EPIVAX, INC.

Basic Information

146 CLIFFORD STREET
PROVIDENCE, RI, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 135531015
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    Amount: $1,474,236.00

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosi ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A

    Amount: $757,712.00

    DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. T1D Tolerance Induction with Natural Treg Epitopes

    Amount: $599,999.00

    DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet ce ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Optimization of a Multivalent Tuberculosis Vaccine

    Amount: $299,908.00

    DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. Epitope-driven deimmunization of Factor VIII

    Amount: $263,867.00

    DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophil ...

    SBIR Phase I 2007 Department of Health and Human Services
  7. A Genome-Derived, Epitope-Driven H. Pylori Vaccine

    Amount: $609,910.00

    DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based appr ...

    SBIR Phase I 2005 Department of Health and Human Services
  8. Novel Smallpox Vaccine Derived from VV/VAR Immunome

    Amount: $1,027,410.00

    DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to de ...

    SBIR Phase I 2005 Department of Health and Human Services
  9. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE

    Amount: $831,922.00

    DESCRIPTION (provided by applicant): EpIVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we describe a r ...

    SBIR Phase I 2004 Department of Health and Human Services
  10. Epitope driven HPV Vaccine Targeting Dentritic Cells

    Amount: $247,768.00

    Human Papilloma Virus (HPV) types 16 and 18 are detected in roughly 70% of all invasive cervical tumors. Among cytologically normal women, detection of HPV infection by PCR has been shown to increase ...

    SBIR Phase I 2001 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government